foxo4 dri senolytic 2023 FOXO4-DRI FOXO4-DRI 10MG | Alpha Omega
FOXO4 DRI 10MG Alpha Omega Peptide FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $5.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



